Literature DB >> 25056392

CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.

M P Goetz1, J N Ingle2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056392      PMCID: PMC4167684          DOI: 10.1038/clpt.2014.99

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  14 in total

1.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Authors:  Matthew P Goetz; James M Rae; Vera J Suman; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

3.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

4.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Authors:  Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

5.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Authors:  William J Irvin; Christine M Walko; Karen E Weck; Joseph G Ibrahim; Wing K Chiu; E Claire Dees; Susan G Moore; Oludamilola A Olajide; Mark L Graham; Sean T Canale; Rachel E Raab; Steven W Corso; Jeffrey M Peppercorn; Steven M Anderson; Kenneth J Friedman; Evan T Ogburn; Zeruesenay Desta; David A Flockhart; Howard L McLeod; James P Evans; Lisa A Carey
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

6.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

7.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.

Authors:  Catherine M Kelly; David N Juurlink; Tara Gomes; Minh Duong-Hua; Kathleen I Pritchard; Peter C Austin; Lawrence F Paszat
Journal:  BMJ       Date:  2010-02-08

8.  CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

Authors:  Matthew P Goetz; Vera J Suman; Tanya L Hoskin; Michael Gnant; Martin Filipits; Stephanie L Safgren; Mary Kuffel; Raimund Jakesz; Margaretha Rudas; Richard Greil; Otto Dietze; Alois Lang; Felix Offner; Carol A Reynolds; Richard M Weinshilboum; Matthew M Ames; James N Ingle
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

9.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Authors:  Werner Schroth; Lydia Antoniadou; Peter Fritz; Matthias Schwab; Thomas Muerdter; Ulrich M Zanger; Wolfgang Simon; Michel Eichelbaum; Hiltrud Brauch
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

10.  The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Authors:  Xianglin Wu; John R Hawse; Malayannan Subramaniam; Matthew P Goetz; James N Ingle; Thomas C Spelsberg
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more
  9 in total

Review 1.  Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Authors:  Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton
Journal:  Am J Epidemiol       Date:  2016-12-17       Impact factor: 4.897

2.  Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.

Authors:  Thomas P Ahern; Lindsay J Collin; James W Baurley; Anders Kjærsgaard; Rebecca Nash; Maret L Maliniak; Per Damkier; Michael E Zwick; R Benjamin Isett; Peer M Christiansen; Bent Ejlertsen; Kristina L Lauridsen; Kristina B Christensen; Rebecca A Silliman; Henrik Toft Sørensen; Trine Tramm; Stephen Hamilton-Dutoit; Timothy L Lash; Deirdre Cronin-Fenton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

Review 3.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

4.  CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.

Authors:  Per Damkier; Anders Kjærsgaard; Kimberly A Barker; Deidre Cronin-Fenton; Anatasha Crawford; Ylva Hellberg; Emilius A M Janssen; Carl Langefeld; Thomas P Ahern; Timothy L Lash
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

5.  Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.

Authors:  Carrie B Hruska; Katie N Hunt; Amy Lynn Conners; Jennifer R Geske; Kathleen R Brandt; Amy C Degnim; Celine M Vachon; Michael K O'Connor; Deborah J Rhodes
Journal:  Breast Cancer Res       Date:  2019-03-08       Impact factor: 6.466

6.  The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.

Authors:  Jeanine Marie Nardin; Werner Schroth; Thais Abreu Almeida; Thomas Mürdter; Solane Picolotto; Evelyn Castillo Lima Vendramini; Reiner Hoppe; Jenifer Primon Kogin; Diandra Miqueleto; Silvia Dark Robaskievicz de Moraes; Matthias Schwab; Roberto Flavio Pecoits-Filho; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  Clin Transl Sci       Date:  2019-11-09       Impact factor: 4.689

7.  (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study.

Authors:  Thais Almeida; Werner Schroth; Jeanine Nardin; Thomas E Mürdter; Stefan Winter; Solane Picolotto; Reiner Hoppe; Jenifer Kogin; Elisa Gaio; Angela Dasenbrock; Raquel Cristina Skrsypcsak; Lucia de Noronha; Matthias Schwab; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  J Pers Med       Date:  2022-03-22

8.  Primary multiple angiosarcoma of vertebra: A case report.

Authors:  Wei Huang; Tao Liu; Ruimeng Duan; Yashuai Yuan; Mingjia Qu; Meng Zhang; Depeng Shang; Xiaobing Yu
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

9.  Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos.

Authors:  Jorge-Aarón Rangel-Méndez; Rodrigo Rubi-Castellanos; Juan-Francisco Sánchez-Cruz; Rosa Esther Moo-Puc
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.